Riskpilot← Back to searchSign inGet full accessADJUTEC PHARMA AS
ASActiveOrg 923831762Ullernchausséen 64, 0379 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20195 employees
Revenue 2024
NOK 0
EBITDA margin
—
+84% vs 2023
Equity ratio
76.8%
Financial strength
Net profit 2024
NOK -1,5M
+85% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -2,1M | +84% |
| Net profit | NOK -1,5M | +85% |
| Total assets | NOK 43,4M | +140% |
| Equity | NOK 33,3M | +85% |
| Employees | 5 | — |
Legal name
ADJUTEC PHARMA AS
Org number
923831762
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21. november 2019
Share capital
NOK 57 750
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Forskning, utvikling, markedsføring og salg av nye hjelpestoffer (adjuvanter) som motvirker antibiotikaresistens, slik at kjente antibiotika virker bedre.
Address
Ullernchausséen 64, 0379 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6 278 | 7 842 | 7 333 | 0 |
| Staff expenses | −0 | −0 | −1 631 | −5 157 | −5 914 | −6 952 |
| EBITDA | 0 | −747 | −5 216 | −23 395 | −13 047 | −2 100 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | −747 | −5 216 | −23 395 | −13 047 | −2 100 |
| Net financials | 0 | −0 | −183 | 173 | −169 | 220 |
| Profit before tax | 0 | −747 | −5 399 | −23 222 | −13 215 | −1 881 |
| Tax | −0 | −0 | −1 883 | −6 072 | −3 681 | −426 |
| Net profit | 0 | −747 | −3 516 | −17 151 | −9 534 | −1 455 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 30 | 1 541 | 32 987 | 33 992 | 18 091 | 43 418 |
| Equity | 24 | 1 277 | 32 760 | 27 601 | 18 067 | 33 345 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 6 | 263 | 227 | 6 391 | 24 | −966 |
| Total debt | 6 | 263 | 227 | 6 391 | 24 | −966 |
EBITDA margin
-210042000.0%
This company
15.8%
Market median
-1329379847% vs market
20192024
Equity ratio
76.8%
This company
38.2%
Market median
+101% vs market
20192024
Return on equity
-4.4%
This company
18.4%
Market median
-124% vs market
20192024
Net profit margin
-145502200.0%
This company
8.1%
Market median
-1796323557% vs market
20192024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192024
Debt / equity
0.30×
This company
0.62×
Market median
+52% vs market
20192024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-10-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JL Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
BK Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Patias Innovation As | Company | 46.3% | 46.3% | 2024 |
Kistefos As | Company | 9.4% | 9.4% | 2024 |
Inven2 As | Company | 5.4% | 5.4% | 2024 |
Helene Sundt As | Company | 4.9% | 4.9% | 2024 |
Tryllebo As | Company | 4.2% | 4.2% | 2024 |
Lemuren As | Company | 3.4% | 3.4% | 2024 |
Weiergangart As | Company | 3.2% | 3.2% | 2024 |
Høse As | Company | 3.1% | 3.1% | 2024 |
Cgs Holding As | Company | 2.4% | 2.4% | 2024 |
Weier As | Company | 2.1% | 2.1% | 2024 |
Linex As | Company | 1.9% | 1.9% | 2023 |
Ken Holding As | Company | 1.8% | 1.8% | 2024 |
Radforsk Investeringsstiftelse | Company | 1.7% | 1.7% | 2024 |
Sundt As | Company | 1.5% | 1.5% | 2024 |
Farvatn Venture As | Company | 1.5% | 1.5% | 2024 |
Adjutec Pharma As | Company | 1.4% | 1.4% | 2024 |
Jandersen Kapital As | Company | 1.4% | 1.4% | 2024 |
Myrlid As | Company | 1.4% | 1.4% | 2024 |
Wibo Consulting As | Company | 1.1% | 1.1% | 2024 |
Algot Invest As | Company | 1.0% | 1.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Patias Innovation As
ADJUTEC PHARMA AS Board members of ADJUTEC PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jethro Lee Holter | Chief Executive Officer | 0 companies |
| Bjørn Klem | Chief Executive Officer | 0 companies |
| Kjell Erik Nordby | Board of Directors | 0 companies |
| Antonius Franciscus Berkien | Board of Directors | 0 companies |
| Nicolaj Refshall Weiergang | Board of Directors | 0 companies |
| Espen Franzon Amundsen | Board of Directors | 0 companies |
| Jonas Einarsson | Board of Directors | 0 companies |
| Jónas Einarsson | Board of Directors | 0 companies |
| Hege Tjørsvaag Brattebø | Board of Directors | 0 companies |
| Øyvind Kongstun Arnesen | Chairman | 0 companies |
| Pål Rongved | Board of Directors | 0 companies |